Effect of dexamethasone on the IGFBP-1 regulation in premature infants during the first weeks of life.
BACKGROUND
Early glucosteroid treatment in preterm infants has a negative impact on physical growth and development. So far, data on dexamethasone effect on the GH/IGF axis and the clinical outcome are conflicting.


OBJECTIVE
Therefore, we studied the effect of dexamethasone treatment on parameters of somatic growth and on the secretion of insulin like growth factors (IGFs) and insulin like growth factors binding proteins (IGFBPs) in preterm infants.


METHODS
In 75 preterm infants somatic development was assessed at birth and after 3 months of corrected age. IGF-I/II and IGFBP-1-3 were measured at the same time. According to their treatment regime the infants were assigned to the dexamethasone treated or the non-treated group.


RESULTS
At 3 months the 13 infants with dexamethasone had a lower body weight, slightly lower body length and a lower head circumference. IGF-II (464.4 +/- 97.4 vs 638 +/- 201.4 mug/l, p = 0.001) and IGFBP-3 (1800 +/- 426 vs 2105 +/- 547 mug/l, p = 0.045) were significantly reduced under the influence of glucocorticoids, whereas IGFBP-1 was elevated (59.6 +/- 61.0 vs 21.1 +/- 21.7 mug/l, p = 0.002). The ratio IGFBP-3/(IGFBP-1 + 2) was reduced in the dexamethasone group (1.827 +/- 0.868 vs 3.098 +/- 1.898 mug/l, p = 0.016), implying a significant retardation in the somatic development.


CONCLUSIONS
Dexamethasone impairs IGF and IGFBP secretion and stimulates IGFBP-1, an inhibitor of IGF-I. These pathways might contribute to alterations of the GH/IGF axis, particularly the ratio IGFBP-3/(IGFBP-1 + 2).
Dost
Axel
A
Department of Pediatrics, Friedrich-Schiller-University, Jena, Germany.
Kauf
Eberhard
E
Schlenvoigt
Dorothea
D
Schramm
Dirk
D
Zintl
Felix
F
Hübler
Axel
A
Pediatr Res. 1998 Aug;44(2):215-21
9702917
Mol Endocrinol. 1997 Nov;11(12):1822-31
9369450
J Clin Endocrinol Metab. 2002 May;87(5):2171-9
11994360
Endocrinology. 1995 Apr;136(4):1403-10
7534698
Endocrinology. 1990 Sep;127(3):1456-62
1696886
Intensive Care Med. 1999 Jul;25(7):717-21
10470576
Endocr J. 1999 Jun;46(3):471-6
10504002
Biol Neonate. 1999 Nov;76(5):283-90
10516395
Clin Endocrinol (Oxf). 2001 Feb;54(2):235-42
11207639
Endocrinology. 2005 Oct;146(10):4274-80
16002526
Am J Physiol Endocrinol Metab. 2003 Nov;285(5):E991-E1000
12902319
Prog Growth Factor Res. 1995;6(2-4):131-40
8817654
J Endocrinol. 2003 Dec;179(3):427-35
14656212
Pediatrics. 2005 Mar;115(3):681-7
15741372
Biochem Biophys Res Commun. 2001 Apr 20;282(5):1126-31
11302732
Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F432-3
12937052
N Engl J Med. 2005 Oct 27;353(17):1802-9
16251536
Paediatr Respir Rev. 2004;5 Suppl A:S321-7
14980290
Pediatrics. 1998 May;101(5):E7
9565440
Pediatrics. 1999 Jul;104(1 Pt 1):91-9
10390266
N Engl J Med. 2001 Jan 11;344(2):95-101
11150359
Drug Saf. 2000 May;22(5):389-404
10830255
J Biol Chem. 1994 Dec 9;269(49):30835-41
7983014
Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E252-61
12670838
Growth Horm IGF Res. 2006 Jun;16(3):185-92
16759894
Am J Perinatol. 1997 Oct;14(9):539-46
9394163
Pediatr Res. 2003 Jul;54(1):37-43
12646720